Cyclin D1 Antikörper

Produktnummer ABIN969007

Produktdetails anti-Cyclin D1 Antikörper

Target: Cyclin D1 (CCND1)

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser Cyclin D1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA

Aufreinigung: purified

Immunogen: Purified recombinant fragment of human CCND1 expressed in E. coli.

Klon: 3D8

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: ELISA: 1:10000, WB: 1:500 - 1:2000

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Ascitic fluid containing 0.03 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: 4°C, -20°C for long term storage

Referenzen für anti-Cyclin D1 Antikörper (ABIN969007)

Kurihara, Oda, Ohishi, Kaneki, Kobayashi, Wake, Tsuneyoshi: "Coincident expression of beta-catenin and cyclin D1 in endometrial stromal tumors and related high-grade sarcomas." in: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, Vol. 23, Issue 2, pp. 225-34, (2010) (PubMed).

Parafioriti, del Bianco, Barisani, Armiraglio, Peretti, Albisetti: "Increased p21 expression in chondrocytes of achondroplasic children independently from the presence of the G380R FGFR3 mutation." in: Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, Vol. 14, Issue 5, pp. 623-30, (2009) (PubMed).

Details zu Cyclin D1

Target: Cyclin D1 (CCND1)

Andere Bezeichnung: CCND1 (CCND1 Produkte)

Synonyme: BCL1 antikoerper, D11S287E antikoerper, PRAD1 antikoerper, U21B31 antikoerper, AI327039 antikoerper, CycD1 antikoerper, Cyl-1 antikoerper, bcl-1 antikoerper, cD1 antikoerper, cb161 antikoerper, cycd1 antikoerper, etID37810.7 antikoerper, fb52e01 antikoerper, fc45c08 antikoerper, fc83a12 antikoerper, id:ibd1198 antikoerper, wu:fb52e01 antikoerper, wu:fc45c08 antikoerper, wu:fc83a12 antikoerper, ccnd1b antikoerper, prad1 antikoerper, ccnd1 antikoerper, ccnd1a antikoerper, bcl1 antikoerper, d11s287e antikoerper, u21b31 antikoerper, CCND1 antikoerper, cyclin D1 antikoerper, cyclin D1 S homeolog antikoerper, cyclin D1 L homeolog antikoerper, CCND1 antikoerper, Ccnd1 antikoerper, ccnd1 antikoerper, ccnd1.S antikoerper, ccnd1.L antikoerper

Hintergrund:

Description: During each cell cycle cyclins undergo periodic accumulation and destruction. As key regulators of the cell cycle the cyclins control important transitions by acting as regulatory subunits of the Cdks. Early in the G1 phase of the cell cycle, cyclin D1 induction is followed by cyclin E induction. This sequential progression is marked early on in G1 by the activation of Cdk4 and in mid to late G1 by the activation of Cdk2 and the hyperphosphorylation of pRB. The final transition into S phase is thought to be dependent on the increased expression and association of cyclin E and Cdk2. In a recent study, Cyclin D1 regulates cellular metabolism, fat cell differentiation and cellular migration. Cyclin D1 is also involved in development and cancer. Cyclin D1 has also been linked to the development and progression of several cancers including breast, bladder, esophagus, and lung.

Aliases: BCL1, PRAD1, U21B31, D11S287E, CCND1

Molekulargewicht: 33.7 kDa

Gen-ID: 595

HGNC: 595

Pathways: PI3K-Akt Signalweg, Zellzyklus, Mitotic G1-G1/S Phases, ER-Nucleus Signaling